Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea

DUBLIN, June 3, 2018 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its investigational treatment solriamfetol demonstrated long-term maintenance of efficacy and a tolerable safety profile in the open-label Phase 3 TONES 5 study of excessive sleepiness (ES) in patients with

New Survey Highlights Lack of Awareness of Neurologic Effects Related to Excessive Sleepiness in Patients with Obstructive Sleep Apnea

New Survey Highlights Lack of Awareness of Neurologic Effects Related to Excessive Sleepiness in Patients with Obstructive Sleep Apnea

May 31, 2018 Survey findings show that while pulmonologists, neurologists and psychiatrists are aware of the negative effects of Excessive Sleepiness (ES) on patients’ quality of life, few are familiar with emerging research linking the condition to brain alterations [1],[2]